Belite Bio (NASDAQ: BLTE) is a San Diego based clinical stage drug development company targeting untreatable eye diseases, such as dry AMD and Stargardt disease (STGD1) which is the most common inherited retinal dystrophy, and metabolic diseases. Its lead pipeline, Tinlarebant (aka LBS-008), is a novel oral once-a-day tablet intended to treat Dry AMD and STGD1 early. Tinlarebant is in phase 3 and has been granted Fast Track & RPD designation in the US, and ODD in the US and EMA for STGD1.